Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ns, thanks for posting. I am glad Judge Hall ruled for Amarin despite lackluster performance by Amarin's attorney in front of Judge Hall.
rose,
1) Pfizer best case % = 40% since Amarin's V cost is 21% + 15% royalty assuming HLS keep the remaining 24%. All non-factual, just my estimate.
2) If KM can do $1B, I am sure PFE can do at least $2.4B
3) I assume PFE's costs and expenses are mostly sunk due to existing sales force.
The fact that PFE is willing to make a deal with HLS to sell V in Canada means PFE is more than willing to sell V in EU and elsewhere. A deal with PFE to sell V in EU should be even more profitable for both sides since there is no middle man, ie., HLS, involved.
Annual Revenue = $2.4B (analyst estimate)
Gross Profit = $1.92B (assume improved gross margin of 80% due to volume)
Amarin's profit before tax = $.96B (assume 50/50 split between PFE&AMRN)
After tax profit = $.72B (assume 25% tax rate)
After tax eps from EU alone = $1.67/share (assume .43B shares outstanding)
Obviously a PFE BO is preferred over partnership.
With treble damage, should the legal threats to Himka be NOW? Unless it counts on appeal via CAFC since chances of drawing both Judge Moore and Newman is less than 5%.
one, Amarin had paid off the debt at the end of Q3 2020.
"rename it shortly?" Great point!
Pfizer Canada put out the following press release on 9/13/21,
https://www.pfizer.ca/new-collaboration-in-cardiovascular-health
Note that there is no mention of Vascepa in the press release. I found that strange as it didn't mention Vascepa in the official press release which tells me either PFE is really salavating over V and try to keep it low profile or PFE doesn't want to publicly associate itself with a drug like Vascepa.
BBI, why PFE needs to pay "$10 billion to $12 billion" when the market is only valuing Amarin at $1.7B in enterprise value. Why didn't PFE pull the trigger now while the going rate is cheap?
"The research “takes things a step further in terms of scientific rigour”, says Deepak Bhatt, a medical researcher at Harvard Medical School in Boston, Massachusetts, who has published research on masking."
https://www.nature.com/articles/d41586-021-02457-y?utm_source=twt_nat&utm_medium=social&utm_campaign=nature
What happen to "Amarin plans to launch VAZKEPA in Germany in September and has filed several market access dossiers in Europe with proposed pricing of approximately €200 per month."
https://investor.amarincorp.com/news-releases/news-release-details/amarin-reports-second-quarter-and-six-month-2021-financial
SVB Leerink bullish on Amarin, initiates with an Outperform
As previously reported, SVB Leerink analyst Roanna Ruiz initiated coverage this morning of Amarin with an Outperform rating and $12 price target. Despite broad use of statins and other low-density lipoprotein cholesterol lowering agents, many patients are not able to reach target levels and are still at risk of experiencing a serious cardiovascular event, the analyst notes. Hence, Ruiz thinks there is a place for Vascepa to help many not well-controlled patients further lower triglycerides and achieve improved cardiovascular risk outcomes. Further, the analyst believes the Vazkepa EU launch is "underappreciated" and that Vazkepa could achieve about $1B peak sales in 2032 due to a much broader EU label and a notably larger EU total addressable market versus that of the U.S. launch. U.S. generics appear to have supply issues in 2021, but Ruiz expects this to resolve as more generics launch in the U.S. in a few years. Thus, the analyst assumes steady year-over-year sales erosion for branded Vascepa from 2023 onwards.
https://theflyonthewall.com/content_index.php?symbol=amrn&days_back=365&table=none
Today's trading pattern is influenced by the SVB upgrade and $12 PT.
Why are Eliquis and Xarelto So Expensive?
https://www.northwestpharmacy.com/special-features/why-are-eliquis-and-xarelto-so-expensive.aspx
Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028
https://www.fiercepharma.com/pharma/bristol-myers-pfizer-score-another-win-their-eliquis-defense-protecting-blockbuster
Thanks Retire for posting. That explains the up 8 cents pre-market move.
Does the governments wants their aging citizens to live longer? If yes, they should extend Vazkepa to as many eligible patients as possible.
Would you like that for AMRN?
Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B,
https://seekingalpha.com/news/3737785-sanofi-strengthens-transplant-business-with-acquisition-of-kadmon-for-19b
Did you use Amarin copay card?
AMRN would have dropped more had IBB not traded as strong today.
Judge Moore is the Chief Justice, not Judge Newman.
Kiwi, did you say Kaiser drop your V copay to $9/month. If true, Kaiser seems to encourage CVD prvention and willing to shell out money for V coverage for its customers. Do you know Kaiser's copay for GV?
Dr. Bhatt will host a panel:
Omega 3 Fatty Acids for CVD Prevention: What's Fishy, What's Fact?
https://www.investorvillage.com/smbd.asp?mb=2294&mn=8695&pt=msg&mid=22365789
Thanks to ltro for posting at ivillage.
Dr. Bhatt will host a panel:
Omega 3 Fatty Acids for CVD Prevention: What's Fishy, What's Fact?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165724362
Thanks to ltro for posting at ivillage.
You said, "My price is $35 the longer $PFE or whovever takes to BO the better for me."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165724362
and you are selling Mar'22 $7 calls?
Exciting new REDUCE-IT data from Dr. Bhatt:
Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD
RF181 - Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD
November 15, 2021, 11:30 AM - 11:35 AM Zone 2
Courtesy of LTRO
https://www.investorvillage.com/smbd.asp?mb=2294&mn=8694&pt=msg&mid=22365721
AHA always takes place in mid-Novemeber. Remember REDUCE-IT data was presented in AHA 2018.
Unfortunately he learned his style from Bernie Madoff.
You are full of sh*t, expecting BO by September 17th yet selling out of money calls which doesn't give you enough premium to buy any AMRN stocks. Full of BS.
which option call and strike?
Posters who expect imminent PFE BO, please buy some AMRN stocks today. Why not? Make some easy money and support the stock at the same time. Without your support, AMRN would most likely break below the important 200 day MA today.
No, I meant:
stillness posted the following:
"Prediction to bank on. Collaboration agreement between Pfizer and Amarin before Sept 17th at a minimum. Most likely sometime next week. Mark it."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165696463
and then you replied:
"Stillness's prediction is based on logical, big pharma strategy."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165701915
That meant you agree with the "before Sept 17th" PFE BO date. Please explain otherwise.
But factual. You should think before you post next time.
I don't need to infer. You stated it clearly in your reply post to stillness.
May I answer for Webster? He believes PFE will BO AMRN on or before September 17 of this year. How do I know? See this post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165701915
Down only 4 cents despite AF and Herper ganging up against AMRN. Why both of those guys need to report the same MO news despite working for the same company, i.e. Stat News?
Due to AF and Herper's negative reporting. How AMRN close today will tell a lot about the stock. If it doesn't hold the 200 day MA, then it's the same old AMRN.
Herper and Feuerstein tweeting negative MO story on AMRN. They are sore losers.
still, if not, please stop posting on this board. I'll do the same if your prediction comes true. Deal?
Only if PFE owned AMRN since we knew Amarin didn't have the pull by itself.